From: Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
Evolocumab (n = 16) | Placebo (n = 14) | P value | |
---|---|---|---|
Age, years | 58.6 (7.6) | 61.4 (7.5) | 0.317 |
Gender, n male (%) | 7 (44) | 7 (50) | 0.732 |
BMI, kg/m2 | 25.5 (3.4) | 26.6 (4.0) | 0.493 |
Smoking, n active (%) | 2 (13) | 0 (0) | 0.171 |
SBP, mmHg | 137 (16) | 139 (12) | 0.574 |
DBP, mmHg | 82 (8) | 86 (8) | 0.317 |
CVD, n (%) | 3 (19) | 1 (7) | 0.351 |
Medication use, n (%) | |||
Statins | 11 (69) | 7 (50) | 0.296 |
Ezetimibe | 3 (19) | 4 (29) | 0.526 |
Total cholesterol, mmol/La | 5.46 (0.92) | 5.62 (0.76) | 0.603 |
LDL-cholesterol, mmol/La | 3.36 (0.70) | 3.68 (0.68) | 0.197 |
HDL-cholesterol, mmol/La | 1.46 (0.43) | 1.35 (0.37) | 0.519 |
Triglycerides, mmol/Lb | 1.38 [1.19–1.54] | 1.28 [0.91–1.63] | 0.533 |
ApoB, g/l | 1.00 [0.93–1.15] | 1.07 [0.92–1.17] | 0.633 |
Lipoprotein(a), nmol/Lc | 254 [182–297] | 154 [138–300] | 0.430 |
hs-CRP, g/l | 0.75 [0.58–1.58] | 1.05[0.53–1.92] | 0.546 |